目的考察多索茶碱和莫西沙星在大鼠体内的药动学特性及合用时的相互作用。方法采用高效液相色谱法测定大鼠给药后不同时间的多索茶碱和莫西沙星的血浆浓度。血浆浓度时间数据用非线性程序WINNONLIN拟合，求得药动学参数。结果两药合用与单独用药时的药-时曲线基本一致,多索茶碱呈一级吸收一级开放式模型，莫西沙星呈一级吸收二室开放式模型，药动学参数无统计学差异。但多索茶碱与莫西沙星合用时，多索茶碱的代谢产物之一茶碱的AUC约是单用多索茶碱时的2倍。结论两药合用药动学上无明显的相互作用, 但莫西沙星有减慢多索茶碱的代谢产物茶碱代谢的趋势，两药可以同时服用，但应注意监测茶碱的血药浓度。
Abstract
OBJECTIVE To study the pharmacokinetic interaction after oral administration of doxofylline and moxifloxacin in rats.METHOD S After oral administration of doxofylline and moxifloxacin,the drug levels in plasma were measured by HPLC.The plasma concentration-time data were accessed by non-linear program (WINNOLIN) and the pharmacokinetic parameters were obtained.The interaction of the pharmacokinetics between doxofylline and moxifloxacine were evaluated by student-t test.RESULTS No significant difference was found on the pharmacokinetic parameters of doxofylline and moxifloxacine before and after co-administration.But the AUC of doxofylline's metabolite theophylline after co-administration was two times higher than single administration.CONCLUSION There was no obvious interaction of pharmacokinetics when doxofylline and moxifloxacin were co-administered.They can be taken simultaneously, but the concentration of theophylline in plasma should be monitored.
关键词
多索茶碱 /
莫西沙星 /
茶碱 /
药动学 /
相互作用
{{custom_keyword}} /
Key words
doxofylline /
moxifloxacin /
theophylline /
pharmacokinetics /
interaction
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
［1］Villani F,Maria PD,Ronchi E,et al.Oral doxophylline in patients with chronic obstructive pulmonary disease［J］.Int J Clin Pharmacol Ther,1997,35(3):107.
［2］Wise R.Areview of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinμLone,and its potentiμL relation to therapeutic efficacy［J］.Clin Drug Invest,1999,17(5):365.
［3］钟淑卿，莫红樱，张永昶,等.氟喹诺酮类对缓释茶碱茶喘平药动学的影响［J］.中华结核和呼吸杂志，1995，18(4)：240.
［4］施毅，康晓明，储小慢，等.环丙沙星和氧氟沙星对氨茶碱药物动力学的影响［J］.中华内科杂志，1994，33(7)：477.
［5］Franzone JS,Cravanzola C,Masera F.Preliminary studies of the absorption,distribution and excretion of 2-(7'-theophyllinemethyl)-1,3-dioxolane in rat［J］.Farmaco (Sci),1981,36(3):220.
［6］Grosa G,Franzone JS，Biglino G.Metabolism of doxofylline by rat liver microsomes［J］.Am Sci Pharmacol & Exp Ther,1986,14(2):33.
［7］Stab H.Moxifloxacin-review of clinical pharmacokinetics me-tabolism and excretion,Poster at First International Moxiflixacia Symposium ［C］.Berlin:Bayer,1993,3:1986.
［8］Stass H,Dalhoff A,Kubitza D,et al.Pharmacokinetics,safety,and tolerbility of ascending single doses of Moxifloxacin, a new 8-methoxy quinolone,administered to healthy subjects［J］.Antimicrob Agents Chemothe,1998,42(8):2060.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
